Woolbright BL - Search Results

1

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.

Rajendran G, Taylor JA 3rd, Woolbright BL. Rajendran G, et al. Among authors: woolbright bl. Cancer Drug Resist. 2021 Mar 19;4(1):69-84. doi: 10.20517/cdr.2020.69. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582013 Free PMC article. Review.

2

SATB1 and bladder cancer: Is there a functional link?

Choudhary D, Clement JM, Choudhary S, Voznesensky O, Pilbeam CC, Woolbright BL, Taylor JA 3rd. Choudhary D, et al. Among authors: woolbright bl. Urol Oncol. 2018 Mar;36(3):93.e13-93.e21. doi: 10.1016/j.urolonc.2017.10.004. Epub 2017 Oct 25. Urol Oncol. 2018. PMID: 29079132

3

Metabolic changes in bladder cancer.

Woolbright BL, Ayres M, Taylor JA 3rd. Woolbright BL, et al. Urol Oncol. 2018 Jul;36(7):327-337. doi: 10.1016/j.urolonc.2018.04.010. Urol Oncol. 2018. PMID: 29773495 Review.

4

The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.

Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, Pilbeam CC, Taylor JA 3rd. Woolbright BL, et al. Mol Cancer Ther. 2018 Sep;17(9):2004-2012. doi: 10.1158/1535-7163.MCT-18-0063. Epub 2018 Jun 15. Mol Cancer Ther. 2018. PMID: 29907593 Free PMC article.

5

Molecular subtyping of bladder cancer: current trends and future directions in 2019.

Smelser WW, Woolbright BL, Taylor JA 3rd. Smelser WW, et al. Among authors: woolbright bl. Curr Opin Urol. 2019 May;29(3):198-202. doi: 10.1097/MOU.0000000000000599. Curr Opin Urol. 2019. PMID: 30855375 Free PMC article. Review.

6

MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential.

Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ, Taylor JA 3rd. Penticuff JC, et al. Among authors: woolbright bl. Nat Rev Urol. 2019 May;16(5):318-328. doi: 10.1038/s41585-019-0171-9. Nat Rev Urol. 2019. PMID: 30914802 Review.

7

Tumor M2-PK: A novel urine marker of bladder cancer.

Liu W, Woolbright BL, Pirani K, Didde R, Abbott E, Kaushik G, Martin P, Hamilton-Reeves J, Taylor JA 3rd, Holzbeierlein JM, Anant S, Lee EK. Liu W, et al. Among authors: woolbright bl. PLoS One. 2019 Jun 27;14(6):e0218737. doi: 10.1371/journal.pone.0218737. eCollection 2019. PLoS One. 2019. PMID: 31246990 Free PMC article.

8

Metabolic Flexibility in Cancer: Targeting the Pyruvate Dehydrogenase Kinase:Pyruvate Dehydrogenase Axis.

Woolbright BL, Rajendran G, Harris RA, Taylor JA 3rd. Woolbright BL, et al. Mol Cancer Ther. 2019 Oct;18(10):1673-1681. doi: 10.1158/1535-7163.MCT-19-0079. Epub 2019 Sep 11. Mol Cancer Ther. 2019. PMID: 31511353 Review.

9

Prostaglandin E2 as a therapeutic target in bladder cancer: From basic science to clinical trials.

Woolbright BL, Pilbeam CC, Taylor JA 3rd. Woolbright BL, et al. Prostaglandins Other Lipid Mediat. 2020 Jun;148:106409. doi: 10.1016/j.prostaglandins.2020.106409. Epub 2020 Jan 10. Prostaglandins Other Lipid Mediat. 2020. PMID: 31931078 Review.

10

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L. Meeks JJ, et al. Among authors: woolbright bl. Nat Rev Urol. 2020 May;17(5):259-270. doi: 10.1038/s41585-020-0304-1. Epub 2020 Mar 31. Nat Rev Urol. 2020. PMID: 32235944 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page